Successful management of refractory immune‐mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti‐VWF nanobody caplacizumab
- 2 January 2024
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 1994-1998
Abstract
Summary: Pregnancy is a potential trigger of acute thrombotic thrombocytopenic purpura (TTP). The management of pregnancy‐associated immune‐mediated TTP (iTTP) can be challenging, especially when it is refractory to standard treatment. Caplacizumab, a nanobody to von Willebrand factor (VWF) blocking its A1 domain, is a valuable new therapeutic option. Its use is, however, not approved during pregnancy and breastfeeding. We describe the successful off‐label administration of caplacizumab during pregnancy and delivery in a patient with refractory iTTP. The favourable outcome without significant thrombotic or haemorrhagic complications indicates that caplacizumab may be an effective and safe treatment option in refractory iTTP during pregnancy.Keywords
This publication has 15 references indexed in Scilit:
- Vacuum-Induced Tamponade for Treatment of Postpartum HemorrhageObstetrics & Gynecology, 2021
- Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working groupBlood, 2020
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 2019
- Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-AnalysisClinical and Applied Thrombosis/Hemostasis, 2019
- Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpuraBlood, 2018
- Thrombotic thrombocytopenic purpuraBlood, 2017
- Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case–control studyOrphanet Journal of Rare Diseases, 2014
- Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomesBlood, 2014
- Survival and relapse in patients with thrombotic thrombocytopenic purpuraBlood, 2010
- Measurement of ADAMTS‐13 activity in plasma by the FRETS‐VWF73 assay: comparison with other assay methodsJournal of Thrombosis and Haemostasis, 2006